Kura Oncology (NASDAQ:KURA) Raised to “Hold” at StockNews.com

Kura Oncology (NASDAQ:KURA) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.

A number of other research analysts have also commented on KURA. Lifesci Capital upgraded Kura Oncology to a “strong-buy” rating in a research report on Tuesday, October 22nd. UBS Group began coverage on Kura Oncology in a research report on Thursday, October 24th. They issued a “buy” rating and a $27.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $32.00 target price on shares of Kura Oncology in a research report on Wednesday, November 6th. JMP Securities reiterated a “market outperform” rating and set a $32.00 price target on shares of Kura Oncology in a research report on Monday, August 12th. Finally, Wedbush restated an “outperform” rating and issued a $37.00 price objective on shares of Kura Oncology in a report on Monday, November 4th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Kura Oncology presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.83.

Kura Oncology Trading Down 4.4 %

Shares of NASDAQ KURA opened at $17.75 on Tuesday. Kura Oncology has a 1-year low of $8.80 and a 1-year high of $24.17. The company has a 50-day moving average of $18.63 and a two-hundred day moving average of $19.97. The company has a market cap of $1.38 billion, a PE ratio of -7.52 and a beta of 0.86. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. nVerses Capital LLC bought a new position in shares of Kura Oncology during the third quarter worth $25,000. SG Americas Securities LLC acquired a new stake in Kura Oncology during the 1st quarter worth $110,000. Quarry LP bought a new position in Kura Oncology during the second quarter worth about $196,000. Entropy Technologies LP acquired a new position in Kura Oncology in the first quarter valued at about $218,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Kura Oncology by 64.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 14,739 shares of the company’s stock worth $288,000 after acquiring an additional 5,788 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.